Matthew C. Riddle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthew C. Riddle has a total of 270 co-authors. Here are the top co-authors by number of shared publications:
- Hertzel C. Gerstein
Population Health Research Institute, McMaster University, Hamilton, ON, Canada
16 shared publications - Geremia B. Bolli
Department of Medicine and Surgery Perugia University Medical School Perugia Italy
8 shared publications Monika Ziemen
Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany
6 shared publicationsJulio Rosenstock
Dallas Diabetes Research Center at Medical City, Dallas, TX
5 shared publicationsPhilip D. Home
Translational and Clinical Research Institute Newcastle University Newcastle upon Tyne UK
5 shared publications- Stephen S. Rich
University of Virginia School of Medicine
5 shared publications
Latest Publications
- Open Access
- 27 April 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (7) , 5527-5541
The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus
In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice daily administration to control the basal metabolism of people with type 1 diabetes (T1DM) and type 2 diabetes (T2DM). This milestone bridged the gap between regimens involving unmodified human insulins of the previous century to those referred to as using ‘designer insulins’, with the introduction 4 years previously of the meal‐time analogue, insulin lispro. The rapid gain in popularity of glargine is explained by its clinical benefits (once‐daily dosing, titration to achieve improved pre‐breakfast plasma glucose, with a lower risk of nocturnal hypoglycaemia compared to NPH, and less frequent blood glucose monitoring). These benefits correlate with the pharmacokinetic/pharmacodynamic characteristics of insulin glargine being closer to physiological BI supply. In T2DM glargine changed the paradigm of insulin substitution by embedding the concept of ‘treating‐to‐target’, by starting BI ‘early’, with focus on near‐normal fasting plasma glucose prior to the introduction of prandial insulin, and more recently in combination with GLP‐1 receptor agonists. These practices/principles have continued with the introduction of additional innovative LAIAs for once‐daily or indeed weekly use. Today glargine remains in widespread worldwide use in people with T1DM and T2DM, is often the initial BI used, while it serves as a reference against which other LAIAs are tested in clinical trials.
- 27 April 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (7) , 5527-5541
Open AccessThe Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus
In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice daily administration to control the basal metabolism of people with type 1 diabetes (T1DM) and type 2 diabetes (T2DM). This milestone bridged the gap between regimens involving unmodified human insulins of the previous century to those referred to as using ‘designer insulins’, with the introduction 4 years previously of the meal‐time analogue, insulin lispro. The rapid gain in popularity of glargine is explained by its clinical benefits (once‐daily dosing, titration to achieve improved pre‐breakfast plasma glucose, with a lower risk of nocturnal hypoglycaemia compared to NPH, and less frequent blood glucose monitoring). These benefits correlate with the pharmacokinetic/pharmacodynamic characteristics of insulin glargine being closer to physiological BI supply. In T2DM glargine changed the paradigm of insulin substitution by embedding the concept of ‘treating‐to‐target’, by starting BI ‘early’, with focus on near‐normal fasting plasma glucose prior to the introduction of prandial insulin, and more recently in combination with GLP‐1 receptor agonists. These practices/principles have continued with the introduction of additional innovative LAIAs for once‐daily or indeed weekly use. Today glargine remains in widespread worldwide use in people with T1DM and T2DM, is often the initial BI used, while it serves as a reference against which other LAIAs are tested in clinical trials.
- 21 March 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (5) , 671-681
The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes
Insulin deficiency, often aggravated by insulin resistance, results in type 2 diabetes mellitus (T2DM). With the availability of glucagon-like peptide 1 receptor agonists and sodium–glucose cotransporter 2 inhibitors, basal insulin (BI) therapy is no longer the first-line option after lifestyle modification plus oral agents is insufficient. In contrast to BI, the newer medications require minor titration, lower hyperglycemia in a glucose-dependent manner, and reduce body weight. Importantly, the newer agents reduce cardiorenal events in the short term. Nonetheless, insulin therapy continues to play a key role in control of hyperglycemia and therefore long-term prevention of vascular complications. Its use is essential in many circumstances, including metabolic emergencies, new diabetes onset, latent autoimmune diabetes (LADA), pregnancy, and when other agents are less desirable due to comorbidities. BI is needed in the frequent condition of failure of other therapies to keep HbA1c to target and/or intolerance of them. There are several advantages to the combination of BI with the newer medications given their different but complementary mechanisms of action, primarily, the lower dose of each, improving adherence and outcomes while decreasing the side effects. Multiple choices for single or combination use can better meet the variety of clinical phenotypes in the heterogeneous T2DM population, using the tenets of precision medicine.
- 21 March 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (5) , 671-681
The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes
Insulin deficiency, often aggravated by insulin resistance, results in type 2 diabetes mellitus (T2DM). With the availability of glucagon-like peptide 1 receptor agonists and sodium–glucose cotransporter 2 inhibitors, basal insulin (BI) therapy is no longer the first-line option after lifestyle modification plus oral agents is insufficient. In contrast to BI, the newer medications require minor titration, lower hyperglycemia in a glucose-dependent manner, and reduce body weight. Importantly, the newer agents reduce cardiorenal events in the short term. Nonetheless, insulin therapy continues to play a key role in control of hyperglycemia and therefore long-term prevention of vascular complications. Its use is essential in many circumstances, including metabolic emergencies, new diabetes onset, latent autoimmune diabetes (LADA), pregnancy, and when other agents are less desirable due to comorbidities. BI is needed in the frequent condition of failure of other therapies to keep HbA1c to target and/or intolerance of them. There are several advantages to the combination of BI with the newer medications given their different but complementary mechanisms of action, primarily, the lower dose of each, improving adherence and outcomes while decreasing the side effects. Multiple choices for single or combination use can better meet the variety of clinical phenotypes in the heterogeneous T2DM population, using the tenets of precision medicine.
- 7 August 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (10) , 4639-4645
ADO09, a co‐formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes
Aim: To study safety, efficacy and weight loss with ADO09, a co‐formulation of insulin A21G and pramlintide, in type 1 diabetes. Materials and Methods: A randomized, two‐arm ambulatory 16‐week study compared ADO09 with insulin lispro in 80 participants with type 1 diabetes. We compared changes of weight, glycated haemoglobin, glycaemic patterns during continuous glucose monitoring, and insulin doses at baseline and at the end of treatment. Results: A significant and continuing weight loss, the primary endpoint, was observed with ADO09 compared with lispro as prandial insulin. In the whole group, the weight loss with ADO09 relative to lispro was 2.1 kg. Glycaemic control was relatively good (7.7% mean glycated haemoglobin) in both groups and did not change during treatment. Prandial insulin doses were reduced by 21% in the ADO09 group, whereas basal insulin dosage was not modified. Gastrointestinal symptoms were more frequent with ADO09, but no clear difference in hypoglycaemia was observed. Conclusions: These results extend previous observations on the efficacy and safety of this insulin/pramlintide co‐formulation. They show a beneficial effect on weight, using less mealtime insulin and without increased hypoglycaemia.
- 7 August 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (10) , 4639-4645
ADO09, a co‐formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes
Aim: To study safety, efficacy and weight loss with ADO09, a co‐formulation of insulin A21G and pramlintide, in type 1 diabetes. Materials and Methods: A randomized, two‐arm ambulatory 16‐week study compared ADO09 with insulin lispro in 80 participants with type 1 diabetes. We compared changes of weight, glycated haemoglobin, glycaemic patterns during continuous glucose monitoring, and insulin doses at baseline and at the end of treatment. Results: A significant and continuing weight loss, the primary endpoint, was observed with ADO09 compared with lispro as prandial insulin. In the whole group, the weight loss with ADO09 relative to lispro was 2.1 kg. Glycaemic control was relatively good (7.7% mean glycated haemoglobin) in both groups and did not change during treatment. Prandial insulin doses were reduced by 21% in the ADO09 group, whereas basal insulin dosage was not modified. Gastrointestinal symptoms were more frequent with ADO09, but no clear difference in hypoglycaemia was observed. Conclusions: These results extend previous observations on the efficacy and safety of this insulin/pramlintide co‐formulation. They show a beneficial effect on weight, using less mealtime insulin and without increased hypoglycaemia.
- Open Access
- 25 March 2024
- Published by American Diabetes Association in Diabetes Care
- Vol. 47 (4) , 556-561
Individualizing Treatment of Type 2 Diabetes After Metformin: More Insights From GRADE
The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) compared several classes of glucose-lowering agents for people wit The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) compared several classes of glucose-lowering agents for people wit
- 25 March 2024
- Published by American Diabetes Association in Diabetes Care
- Vol. 47 (4) , 556-561
Open AccessIndividualizing Treatment of Type 2 Diabetes After Metformin: More Insights From GRADE
The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) compared several classes of glucose-lowering agents for people wit The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) compared several classes of glucose-lowering agents for people wit
- 2 April 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (5)
Cover Image
- Open Access
- 23 March 2023
- Published by American Diabetes Association in Diabetes Care
- Vol. 46 (4) , 665-666
Reducing Bias in Academic Publishing: TheDiabetes CareApproach
The potential for bias, be it based on gender, socioeconomics, or race/ethnicity, is a concern in nearly every aspect of life. Reduction in all forms of in The potential for bias, be it based on gender, socioeconomics, or race/ethnicity, is a concern in nearly every aspect of life. Reduction in all forms of in
- 23 March 2023
- Published by American Diabetes Association in Diabetes Care
- Vol. 46 (4) , 665-666
Open AccessReducing Bias in Academic Publishing: TheDiabetes CareApproach
The potential for bias, be it based on gender, socioeconomics, or race/ethnicity, is a concern in nearly every aspect of life. Reduction in all forms of in The potential for bias, be it based on gender, socioeconomics, or race/ethnicity, is a concern in nearly every aspect of life. Reduction in all forms of in
- 31 January 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (5) , 1241-1248
A co‐formulation of pramlintide and insulin A21G ( ADO09 ) improves postprandial glucose and short‐term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes
Aim: Pramlintide improves postprandial glucose but requires additional injections. We investigated the pharmacokinetics/pharmacodynamics, efficacy and safety of ADO09, pramlintide/insulin A21G co‐formulation, in type 1 diabetes (T1D). Materials and Methods: This double‐blinded, randomized, two‐period cross‐over study compared prandial administration of ADO09 or insulin aspart over 24 days in T1D using either ≤40 U bolus insulin per day [low‐dose group (LD), n = 28] or 40‐75 U [high‐dose group (HD), n = 16]. Glycaemic responses through continuous glucose monitoring, and pharmacokinetics/pharmacodynamics profiles following mixed‐meal‐tolerance tests were evaluated at baseline and at the end of treatment. Results: Glucose increments from 0 to 4 h after mixed‐meal‐tolerance test (primary endpoint) were 39% (not statistically significantly) lower with ADO09 in the low‐dose group and 69% lower in the high‐dose group. Mean continuous glucose monitoring glucose during ambulatory treatment was lower with ADO09 than with aspart (LD: –8.2 ± 7.9 mg/dl, p = .0001; HD: –7.0 ± 10 mg/ml, p = .0127), and time‐in‐range (70–180 mg/dl) improved (LD: +4%, p = .0134; HD: +4%, p = .0432). Body weight declined significantly with ADO09 (LD: –0.8 kg; HD: –1.6 kg). Hypoglycaemic events were slightly more frequent with ADO09 versus aspart (LD: 142 vs. 115; HD: 96 vs. 79). Gastrointestinal events occurred more frequently with ADO09 but were generally transient, and no other safety signals were identified. Conclusions: In comparison with aspart, ADO09 was well tolerated and effective in T1D across a wide range of dosage, significantly improving the average blood glucose level and body weight during 24 days of ambulatory treatment. Meal test profiles confirmed improvement of glycaemic patterns and other responses with ADO09.
- 31 January 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (5) , 1241-1248
A co‐formulation of pramlintide and insulin A21G ( ADO09 ) improves postprandial glucose and short‐term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes
Aim: Pramlintide improves postprandial glucose but requires additional injections. We investigated the pharmacokinetics/pharmacodynamics, efficacy and safety of ADO09, pramlintide/insulin A21G co‐formulation, in type 1 diabetes (T1D). Materials and Methods: This double‐blinded, randomized, two‐period cross‐over study compared prandial administration of ADO09 or insulin aspart over 24 days in T1D using either ≤40 U bolus insulin per day [low‐dose group (LD), n = 28] or 40‐75 U [high‐dose group (HD), n = 16]. Glycaemic responses through continuous glucose monitoring, and pharmacokinetics/pharmacodynamics profiles following mixed‐meal‐tolerance tests were evaluated at baseline and at the end of treatment. Results: Glucose increments from 0 to 4 h after mixed‐meal‐tolerance test (primary endpoint) were 39% (not statistically significantly) lower with ADO09 in the low‐dose group and 69% lower in the high‐dose group. Mean continuous glucose monitoring glucose during ambulatory treatment was lower with ADO09 than with aspart (LD: –8.2 ± 7.9 mg/dl, p = .0001; HD: –7.0 ± 10 mg/ml, p = .0127), and time‐in‐range (70–180 mg/dl) improved (LD: +4%, p = .0134; HD: +4%, p = .0432). Body weight declined significantly with ADO09 (LD: –0.8 kg; HD: –1.6 kg). Hypoglycaemic events were slightly more frequent with ADO09 versus aspart (LD: 142 vs. 115; HD: 96 vs. 79). Gastrointestinal events occurred more frequently with ADO09 but were generally transient, and no other safety signals were identified. Conclusions: In comparison with aspart, ADO09 was well tolerated and effective in T1D across a wide range of dosage, significantly improving the average blood glucose level and body weight during 24 days of ambulatory treatment. Meal test profiles confirmed improvement of glycaemic patterns and other responses with ADO09.
- 3 January 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (4) , 1125-1129
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial
- 3 January 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (4) , 1125-1129
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial
- 11 July 2022
- Published by American Diabetes Association in Diabetes Care
- Vol. 45 (9) , 2152-2155
Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study
OBJECTIVE: To use protein biomarkers to identify people with type 2 diabetes at high risk of cardiovascular outcomes and death. RESEARCH DESIGN AND METHODS: Biobanked serum from 4,957 ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) trial participants was analyzed. Forward-selection Cox models identified independent protein risk factors for major adverse cardiovascular events (MACE) and death that were compared with a previously validated biomarker panel. RESULTS: NT-proBNP and osteoprotegerin predicted both outcomes. In addition, trefoil factor 3 predicted MACE, and angiopoietin-2 predicted death (C = 0.70 and 0.79, respectively, compared with 0.63 and 0.66 for clinical variables alone). These proteins had all previously been identified and validated. Notably, C statistics for just NT-proBNP plus clinical risk factors were 0.69 and 0.78 for MACE and death, respectively. CONCLUSIONS: NT-proBNP and other proteins independently predict cardiovascular outcomes in people with type 2 diabetes following acute coronary syndrome. Adding other biomarkers only marginally increased NT-proBNP’s prognostic value.
- 11 July 2022
- Published by American Diabetes Association in Diabetes Care
- Vol. 45 (9) , 2152-2155
Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study
OBJECTIVE: To use protein biomarkers to identify people with type 2 diabetes at high risk of cardiovascular outcomes and death. RESEARCH DESIGN AND METHODS: Biobanked serum from 4,957 ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) trial participants was analyzed. Forward-selection Cox models identified independent protein risk factors for major adverse cardiovascular events (MACE) and death that were compared with a previously validated biomarker panel. RESULTS: NT-proBNP and osteoprotegerin predicted both outcomes. In addition, trefoil factor 3 predicted MACE, and angiopoietin-2 predicted death (C = 0.70 and 0.79, respectively, compared with 0.63 and 0.66 for clinical variables alone). These proteins had all previously been identified and validated. Notably, C statistics for just NT-proBNP plus clinical risk factors were 0.69 and 0.78 for MACE and death, respectively. CONCLUSIONS: NT-proBNP and other proteins independently predict cardiovascular outcomes in people with type 2 diabetes following acute coronary syndrome. Adding other biomarkers only marginally increased NT-proBNP’s prognostic value.
- Open Access
- 6 July 2022
- Published by American Diabetes Association in Diabetes Care
- Vol. 45 (7) , 1493-1494
Editorial Cycles and Continuity of Diabetes Care
We all live by natural and humanly imposed cycles leading to yearly, monthly, and daily routines. This month, Diabetes Care completes a cycle of editorial leade
- 6 July 2022
- Published by American Diabetes Association in Diabetes Care
- Vol. 45 (7) , 1493-1494
Open AccessEditorial Cycles and Continuity of Diabetes Care
We all live by natural and humanly imposed cycles leading to yearly, monthly, and daily routines. This month, Diabetes Care completes a cycle of editorial leade